Shares of Rocket Pharmaceuticals (NASDAQ: RCKT) gained almost 4% yesterday in the extended trading hours on insider trading news. One of the major owners, RTW Investments, LP, lapped up 1,355,932 shares of RCKT stock at an average price of $14.75 per share, worth $20 million.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Based in the U.S., Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, focused on the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases.
With the recently reported Buys, the firm now owns 26.69% (17.63 million shares) of the total shares outstanding, with a value of $294.75 million.
Interestingly, TipRanks also provides a list of hot stocks that boasts either a Very Positive or Positive insider confidence signal.
Is Rocket Pharmaceuticals, Inc. (RCKT) a Buy, Sell, or Hold?
The Wall Street community is clearly optimistic about the stock. Overall, the stock commands a Strong Buy consensus rating based on nine unanimous Buys. Rocket Pharmaceuticals stock’s average price target of $57.71 implies a whopping 250.2% upside potential from current levels.
Further, RCKT stock boasts a score of 9 out of 10 on TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations.
Read full Disclosure